High-Risk Pregnancies Require More Emotional Support
Women with medically high-risk pregnancies feel they need to suppress their feelings of stress to protect the health of their fetus.
Related Articles
AIRFLOW-3 Data for Targeted Lung Denervation in COPD, with Gerard Criner, MD
Criner reviews findings from AIRFLOW-3 and describes the subgroup of targeted lung denervation treatment responders being targeted in AIRFLOW-4.
American Thoracic Society International Conference
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
Recognizing the Burden of Sarcopenia in COPD, with Amy Attaway, MD
Attaway describes the importance of screening for and treating sarcopenia in patients with COPD and clinical gaps that complicate this process.
American Thoracic Society International Conference
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
FDA Warns About Rare, Severe Itching After Stopping Cetirizine or Levocetirizine
The allergy medications of cetirizine or levocetirizine have led to pruritus in some patients who stopped using the medications after using them daily for a…
American Thoracic Society International Conference
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
Study Highlights Impact of Rademikibart on Blood Eosinophil Counts in Asthma
This analysis highlights rademikibart’s effect on blood eosinophil counts in those with asthma, exploring whether there was an IL-4Rα class effect.
Acne, Rosacea Trends in 2025, with Shanna Miranti, PA-C
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
Rademikibart Improves Lung Function in Patients with Asthma within 24 Hours
This analysis highlights the rapid improvements seen in patients with uncontrolled asthma within 24 hours of their initial rademikibart dose.
Dupilumab Improves Asthma Control Among Children Despite Duration of Condition
In this analysis, investigators found consistent benefits over placebo among children with type 2 asthma treated with dupilumab, regardless of condition length.